Recruiting
Interstitial lung disease
RecruitingStudy on the Effects of Wharton's Jelly Mesenchymal Stem Cells, Pirfenidone, and Nintedanib for Patients with Fibrotic Interstitial Lung Disease
Registered drug
Study on the Effects of Wharton's Jelly Mesenchymal Stem Cells, Pirfenidone, and Nintedanib for Patients with Fibrotic Interstitial Lung Disease
Registered drug
- Disease:Interstitial lung disease
- Substances:NintedanibPirfenidone+1
Countries:
Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Nintedanib
